Bayer (Cell Therapy Mfg) vs Cedars-Sinai Biomanufacturing: CDMO Comparison

How does Bayer (Cell Therapy Mfg) compare to Cedars-Sinai Biomanufacturing for Cell Therapy manufacturing?

Side-by-side comparison of Bayer (Cell Therapy Mfg) and Cedars-Sinai Biomanufacturing on independent FDA inspections, EMA and MHRA GMP certificates, clinical-program activity, and CDMO Signal Score. Data sourced from FDA, EMA EudraGMDP, MHRA GMDP, and ClinicalTrials.gov.

Berkeley, CA
Signal Score
79/100
Quality (FDA + GMP)
87/100
FDA inspections
8
— NAI / VAI / OAI
5 / 2 / 1
FDA warning letters
0
EMA GMP certificates (active)
16
MHRA GMP certificates (compliant)
1
Clinical programs (matched)
126
Capacity
Modalities
Cell Therapy, Gene Editing
Los Angeles, CA
Signal Score
79/100
Quality (FDA + GMP)
100/100
FDA inspections
1
— NAI / VAI / OAI
1 / 0 / 0
FDA warning letters
0
EMA GMP certificates (active)
0
MHRA GMP certificates (compliant)
0
Clinical programs (matched)
34
Capacity
Modalities
Cell Therapy, Gene Editing

Key differences

  • Bayer (Cell Therapy Mfg) has more FDA inspections on record (8 vs 1) — a deeper regulatory paper trail.
  • Cedars-Sinai Biomanufacturing carries a cleaner inspection mix — no OAI classifications versus 1 for Bayer (Cell Therapy Mfg).
  • Bayer (Cell Therapy Mfg) holds 16 active EMA GMP certificates; Cedars-Sinai Biomanufacturing does not appear in EudraGMDP.
  • Bayer (Cell Therapy Mfg) maintains 1 MHRA / UK GMP certificate; Cedars-Sinai Biomanufacturing does not.
  • Bayer (Cell Therapy Mfg) appears as a manufacturing partner on more matched clinical programs (126 vs 34) — a broader sponsor book.

On a 13-modality CDMO landscape, both Bayer (Cell Therapy Mfg) and Cedars-Sinai Biomanufacturing qualify as Cell Therapy manufacturers; Bayer (Cell Therapy Mfg) carries the higher composite Signal Score for Cell Therapy programs in this comparison.

What to evaluate for Cell Therapy programs

Both Bayer (Cell Therapy Mfg) and Cedars-Sinai Biomanufacturing qualify as Cell Therapy CDMOs. When choosing between them for Cell Therapy programs, weigh these four dimensions specifically — each carries through to the side-by-side scorecard above.

Autologous vs allogeneic

Autologous needs per-patient scheduling, chain-of-identity, and short turnaround; allogeneic needs scalable batch processing and a master cell bank strategy. Pick a CDMO proven in your model.

Vector & raw materials

Most cell therapies need a viral vector. Confirm whether the CDMO makes vector in-house or coordinates an external supplier, and how that affects timelines.

Closed-system & cleanrooms

Closed, automated processing reduces contamination risk and labor. Ask about cleanroom grade, automation platforms, and parallel-suite capacity.

Cold chain & logistics

Cryopreservation and chain-of-custody are critical for living cells. Evaluate the CDMO's cold-chain and apheresis-to-infusion logistics.

See all Cell Therapy CDMOs ranked by Signal Score →

Frequently asked: Bayer (Cell Therapy Mfg) vs Cedars-Sinai Biomanufacturing

How does Bayer (Cell Therapy Mfg) compare to Cedars-Sinai Biomanufacturing for Cell Therapy manufacturing?

On CDMO Signal's composite Signal Score, Bayer (Cell Therapy Mfg) is 79/100 and Cedars-Sinai Biomanufacturing is 79/100; Bayer (Cell Therapy Mfg) has 8 FDA inspections on record vs 1 for Cedars-Sinai Biomanufacturing; European coverage is 17 active EMA+MHRA certificates for Bayer (Cell Therapy Mfg) vs 0 for Cedars-Sinai Biomanufacturing. Both are tracked in the CDMO Signal directory as Cell Therapy CDMOs. The scorecard above breaks down every metric side by side — use it alongside each CDMO's individual profile for the full regulatory and clinical footprint.

Which has the stronger FDA inspection record, Bayer (Cell Therapy Mfg) or Cedars-Sinai Biomanufacturing?

Bayer (Cell Therapy Mfg) has 8 FDA inspections on record (NAI 5 / VAI 2 / OAI 1) and 0 warning letters. Cedars-Sinai Biomanufacturing has 1 FDA inspection on record (NAI 1 / VAI 0 / OAI 0) and 0 warning letters.

How do Bayer (Cell Therapy Mfg) and Cedars-Sinai Biomanufacturing compare on European GMP coverage?

Bayer (Cell Therapy Mfg) holds 16 active EMA GMP certificates and 1 MHRA / UK certificate. Cedars-Sinai Biomanufacturing holds 0 active EMA GMP certificates and 0 MHRA / UK certificates. Use these counts as a proxy for the breadth of each CDMO's European regulatory footprint.

Which is more active in clinical-stage manufacturing — Bayer (Cell Therapy Mfg) or Cedars-Sinai Biomanufacturing?

Bayer (Cell Therapy Mfg) is matched to 126 ClinicalTrials.gov records as a manufacturing partner; Cedars-Sinai Biomanufacturing is matched to 34. Higher counts indicate broader sponsor exposure but say nothing about approved-product track record — pair this number with each CDMO's profile page for context.

Which is better for Cell Therapy manufacturing — Bayer (Cell Therapy Mfg) or Cedars-Sinai Biomanufacturing?

Both Bayer (Cell Therapy Mfg) and Cedars-Sinai Biomanufacturing are tagged as Cell Therapy CDMOs in our directory, so both are credible options for Cell Therapy programs. The most important differentiator for Cell Therapy selection is typically autologous vs allogeneic: Autologous needs per-patient scheduling, chain-of-identity, and short turnaround; allogeneic needs scalable batch processing and a master cell bank strategy. Pick a CDMO proven in your model. Review each CDMO's profile and inspection record before shortlisting.

Evaluating Bayer (Cell Therapy Mfg) and Cedars-Sinai Biomanufacturing for a program?

Use the free AI matchmaker to weigh both against your specific requirements — capacity, modality, regulatory record, geography — and surface other qualified options.

Find & compare CDMOs →
Sourced from FDA, EMA EudraGMDP, MHRA GMDP, and ClinicalTrials.gov.